An open label, randomizing, multicenter, phase III, comparator controlled parallel group study to assess the long term safety and efficacy of Lanthanum Carbonate in CRF patients recieving hemodialysis.

Grants and Contracts Details

StatusFinished
Effective start/end date1/1/01 → 6/30/04

Funding

  • Shire Laboratories Inc: $154,614.00